Listed

Journey Medical Corp: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Aug 12, 2025 and accepted by EDGAR at Aug 12, 2025, 16:36 ET.

Share

Management's discussion and analysis

As filed, 32,737 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Certain matters discussed in this report may constitute forward-looking statements for purposes of the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “expect,” “will,” “could,” “project,” “should,” “intend” and similar expressions are generally intended to identify forward-looking statements. Our actual results may differ materially from the results anticipated in or implied by these forward-looking statements due to a variety of factors, including, without limitation:

  • the fact that our products and product candidates are subject to time and cost intensive regulation and clinical testing and as a result, may never be successfully developed or commercialized;
  • a substantial portion of our sales derive from products that are without patent protection and/or are or may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market share of existing competitor products, any of which could have a significant adverse impact on our operating income;
  • we operate in a heavily regulated industry, and we cannot predict the impact that any future legislation or administrative or executive action may have on our operations;
  • our revenue is dependent mainly upon sales of our dermatology products and any setback relating to the sale of such products could impair our operating results;
  • competition could limit our products’ commercial opportunity and profitability, including competition from manufacturers of generic versions of our products;
  • the risk that our products do not achieve broad market acceptance, including by government and third-party payors;
  • our reliance on third parties for several aspects of our operations;
  • our dependence on our ability to identify, develop, and acquire or in-license products and integrate them into our operations, at which we may be unsuccessful;
  • the dependence of the success of our business, including our ability to finance our company and generate additional revenue, on the successful commercialization of EmrosiTM and the successful development, regulatory approval and commercialization of any future product candidates that we may develop, in-license or acquire;
  • clinical drug development is very expensive, time consuming, and uncertain and our clinical trials may fail to adequately demonstrate the safety and efficacy of our current or any future product candidates;
  • our competitors could develop and commercialize products similar or identical to ours;
  • risks related to the protection of our intellectual property and our potential inability to maintain sufficient patent protection for our technology and products;
  • our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or our third parties’ cybersecurity;
  • the effects of major public health issues, epidemics or pandemics on our product revenues and any future clinical trials;
  • our potential need to raise additional capital;
  • the substantial doubt expressed about our ability to continue as a going concern;
  • Fortress controls a voting majority of our common stock, which could be detrimental to our other shareholders; and
  • the risks described under the section titled “Risk Factors” in Item 1A below and in our Annual Report on Form 10-K for the year ended December 31, 2024 (the “2024 Form 10-K”).

The forward-looking statements contained in this report reflect our views and assumptions as of the effective date of this report. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. Except as required by law, we assume no responsibility for updating any forward-looking statements.

We qualify all of our forward-looking statements by these cautionary statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Overview

We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We are managed by experienced life science executives with a track record of creating value for their stakeholders and bringing novel medicines to the market, enabling patients to experience increased quality of life and physicians and other licensed medical professionals to provide better care for their patients. We acquire rights to products and product candidates by licensing or otherwise acquiring an ownership interest in, funding the research and development of, and eventually commercializing the products through our field sales organization. We are a controlled subsidiary of Fortress Biotech, Inc. (“Fortress” or “Parent”).

Recent Corporate Highlights

Effective after the close of U.S equity markets on June 27, 2025, we joined the small cap Russell 2000® Index and the broad-market Russell 3000® Index as a result of the 2025 annual Russell Index reconstitution.

On November 1, 2024, the FDA approved EmrosiTM (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29 (“Emrosi”), for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed by Journey in collaboration with Dr. Reddy’s Laboratories, Ltd. (“DRL”). Our initial supply became available in March 2025. In addition, the initial distribution of Emrosi to pharmacies is ongoing and the first Emrosi prescriptions have been filled. We began sales promotion of Emrosi in April 2025, and are commercializing Emrosi in the U.S. with our existing commercial team.

Critical Accounting Polices and Uses of Estimates

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States. Applying these principles requires our judgment in determining the appropriateness of acceptable accounting principles and methods of application in diverse and complex economic activities. The preparation of the accompanying financial statements requires us to make estimates and judgments that affect the reported amounts of revenues, expenses, assets and liabilities, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and other assumptions that we believe are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For a discussion of our critical accounting estimates, see the section of the 2024 Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Use of Estimates.” There were no material changes in our critical accounting estimates or accounting policies from December 31, 2024.

Accounting Pronouncements

During the six-month period ended June 30, 2025, there were no new accounting pronouncements or updates to recently issued accounting pronouncements disclosed in the 2024 Form 10-K that are expected to materially affect the Company’s present or future financial statements.

Emerging Growth Company and Smaller Reporting Company Status

We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in our annual reports on Form 10-K, an exemption from the requirement to provide an auditor’s report on internal controls over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, as amended, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.

We are also a “smaller reporting company,” meaning that either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) the market value of our shares held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. As a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K, we have reduced disclosure obligations regarding executive compensation, and smaller reporting companies are permitted to delay adoption of certain recent accounting pronouncements discussed in Note 2 to our consolidated financial statements in this report on Form 10-Q.

Results of Operations

The following table summarizes our results of operations for the three-month periods ended June 30, 2025 and 2024:

Comparison of the Three-Month Periods Ended June 30, 2025 and 2024

($ in thousands, except per share data)

​ ​ Revenue: ​ ​ ​ ​ ​ Three-Month Periods Ended June 30, 2025 ​ ​ ​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Product revenue, net $15,009 $14,855 ​ $154 ​ 1%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Cost of goods sold – (excluding amortization of acquired intangible assets) ​ 4,939 ​ 5,727 ​ ​ (788) ​ -14%
Amortization of acquired intangible assets ​ ​ 1,064 ​ ​ 814 ​ ​ 250 ​ 31%
Research and development ​ — ​ 913 ​ ​ (913) ​ -100%
Selling, general and administrative ​ 11,882 ​ 10,328 ​ ​ 1,554 ​ 15%
Total operating expenses ​ 17,885 ​ 17,782 ​ ​ 103 ​ 1%
Loss from operations ​ (2,876) ​ (2,927) ​ ​ 51 ​ -2%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Other expense (income) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Interest income ​ (138) ​ (161) ​ ​ 23 ​ -14%
Interest expense ​ ​ 937 ​ ​ 563 ​ ​ 374 ​ 66%
Foreign exchange transaction losses ​ ​ 61 ​ ​ 32 ​ ​ 29 ​ 91%
Total other expense (income) ​ 860 ​ 434 ​ ​ 426 ​ 98%
Loss before income taxes ​ ​ (3,736) ​ ​ (3,361) ​ ​ (375) ​ 11%
Income tax expense ​ 60 ​ — ​ ​ 60 ​ 100%
Net loss ​ $(3,796) ​ $(3,361) ​ $(435) ​ 13%

Revenues

The following table reflects our net product revenue for the three-month periods ended June 30, 2025 and 2024:

($ in thousands)

​ ​ ​ ​ ​ ​ ​ ​ Three-Month Periods Ended June 30, 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​ ​ ​ ​
EmrosiTM ​ $2,795 ​ $— ​ $2,795 ​ 100%
Qbrexza® ​ ​ 6,949 ​ ​ 6,836 ​ ​ 113 ​ 2%
Accutane® ​ ​ 3,395 ​ ​ 5,719 ​ ​ (2,324) ​ -41%
Amzeeq® ​ ​ 879 ​ ​ 1,205 ​ ​ (326) ​ -27%
Zilxi® ​ ​ 256 ​ ​ 369 ​ ​ (113) ​ -31%
Other / legacy ​ ​ 735 ​ ​ 726 ​ ​ 9 ​ 1%
Total net product revenue ​ $15,009 ​ $14,855 ​ $154 ​ 1%

Total net product revenues of $15.0 million for the second quarter of 2025 were consistent with $14.9 million of net product revenues for the second quarter of 2024. The second quarter of 2025 includes $2.8 million of incremental net product revenue related to the U.S. commercial launch of Emrosi™, offset by a decrease in Accutane, as a result of lower sales volume driven by recent market competition.

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.

Gross-to-net sales accruals and the balance in the related allowance accounts for the three-month periods ended June 30, 2025 and 2024, were as follows:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of March 31, 2025 ​ $2,601 ​ $8,668 ​ $3,440 ​ $761 ​ $15,470
Current provision related to sales in the current period ​ ​ 222 ​ ​ 28,735 ​ ​ 6,239 ​ ​ 1,401 ​ ​ 36,597
Checks/credits issued to third parties ​ ​ (324) ​ ​ (30,623) ​ ​ (5,885) ​ ​ (1,343) ​ ​ (38,175)
Balance as of June 30, 2025 ​ $2,499 ​ $6,780 ​ $3,794 ​ $819 ​ $13,892

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of March 31, 2024 ​ $2,806 ​ $2,757 ​ $3,445 ​ $938 ​ $9,946
Current provision related to sales in the current period ​ ​ 1,112 ​ ​ 23,573 ​ ​ 6,492 ​ ​ 1,722 ​ ​ 32,899
Checks/credits issued to third parties ​ ​ (704) ​ ​ (24,566) ​ ​ (6,134) ​ ​ (1,631) ​ ​ (33,035)
Balance as of June 30, 2024 ​ $3,214 ​ $1,764 ​ $3,803 ​ $1,029 ​ $9,810

Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were $13.9 million at June 30, 2025, compared to $9.8 million at June 30, 2024, an increase of $4.1 million. The increase is due to the coupon rebate allowance related to the launch and commercialization of Emrosi.

Cost of Goods Sold - (excluding amortization of acquired intangible assets)

Cost of goods sold - (excluding amortization of acquired intangible assets) decreased by $0.8 million, or 14%, to $4.9 million for the three-month period ended June 30, 2025, from $5.7 million for the three-month period ended June 30, 2024, due to lower overall product cost of goods related to product sales mix, driven mainly by the decrease in Accutane revenue, which has a higher cost to Journey than Emrosi.

Amortization of acquired intangible assets

Amortization of acquired intangible assets increased by $0.3 million, or 31%, to $1.1 million for the three-month period ended June 30, 2025, from $0.8 million for the three-month period ended June 30, 2024, driven by the addition of the Emrosi acquired intangible asset upon our payment to DRL of the milestone payment triggered by the FDA’s approval of Emrosi in November 2024.

Research and Development

Research and development costs were nil in the second quarter of 2025, compared to $0.9 million in the second quarter of 2024. The second quarter of 2024 includes Emrosi pre-approval project expenses.

Selling, General and Administrative

Selling, general and administrative expenses increased by $1.6 million, or 15%, to $11.9 million for the three-month period ended June 30, 2025, from $10.3 million for the three-month period ended June 30, 2024. The increase is primarily due to the incremental operational activities related to the launch and commercialization of Emrosi.

Interest Expense, net

Interest expense, net increased by $0.4 million, to $0.8 million for the three-month period ended June 30, 2025, from $0.4 million for the three-month period ended June 30, 2024. The increase is primarily attributable to a higher principal balance outstanding under the Credit Agreement with SWK (each as defined below) during the three months ended June 30, 2025 of $25.0 million as compared to an average of approximately $15.0 million during the three months ended June 30, 2024.

Comparison of the Six-Month Periods Ended June 30, 2025 and 2024

($in thousands, except per share data)

​ ​ Revenue: ​ ​ ​ Six-Month Periods Ended June 30, 2025 ​ ​ ​ ​ 2024 ​ ​ ​ ​ ​ Change $​% ​ ​ ​ ​ ​ ​ ​ ​
Product revenue, net ​ $28,148 ​ $27,885 ​ $263 ​ ​ 1%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Operating expenses ​ ​ ​ ​ ​ ​
Cost of goods sold – (excluding amortization of acquired intangible assets) ​ 9,729 ​ 11,728 ​ (1,999) ​ ​ -17%
Amortization of acquired intangible assets ​ 2,129 ​ 1,629 ​ 500 ​ ​ 31%
Research and development ​ 39 ​ 8,797 ​ (8,758) ​ ​ -100%
Selling, general and administrative ​ 22,451 ​ 18,748 ​ 3,703 ​ ​ 20%
Total operating expenses ​ 34,348 ​ 40,902 ​ (6,554) ​ ​ -16%
Loss from operations ​ (6,200) ​ (13,017) ​ 6,817 ​ ​ -52%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Other expense (income) ​ ​ ​ ​ ​ ​
Interest income ​ (287) ​ (378) ​ 91 ​ ​ -24%
Interest expense ​ 1,828 ​ 1,111 ​ 717 ​ ​ 65%
Foreign exchange transaction losses ​ 68 ​ 53 ​ 15 ​ ​ 28%
Total other expense (income) ​ 1,609 ​ 786 ​ 823 ​ ​ 105%
Loss before income taxes ​ (7,809) ​ (13,803) ​ 5,994 ​ ​ -43%
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Income tax expense ​ 60 ​ — ​ 60 ​ ​ 100%
Net loss ​ $(7,869) ​ $(13,803) ​ $5,934 ​ ​ -43%

Revenues

The following table reflects our net product revenue for the six-month periods ended June 30, 2025 and 2024:

($in thousands)

​ ​ ​ ​ ​ ​ ​ Six-Month Periods Ended June 30 2025 ​ ​ ​ 2024 ​ ​ ​ ​ ​ Change $% ​ ​ ​ ​
EmrosiTM ​ $4,865 ​ $— ​ 4,865 ​ ​ 100%
Qbrexza® ​ 12,110 ​ 11,853 ​ 257 ​ ​ 2%
Accutane® ​ 7,050 ​ 11,538 ​ (4,488) ​ ​ -39%
Amzeeq® ​ 1,979 ​ 1,960 ​ 19 ​ ​ 1%
Zilxi® ​ 682 ​ 642 ​ 40 ​ ​ 6%
Other / legacy ​ 1,462 ​ 1,892 ​ (430) ​ ​ -23%
Total net product revenue ​ $28,148 ​ $27,885 ​ $263 ​ ​ 1%

Total net product revenues increased by $0.3 million, to $28.2 million for the six months ended June 30, 2025 from $27.9 million for the six months ended June 30, 2024. The six months ended June 30, 2025 includes $4.9 million of incremental net product revenue related to the U.S. commercial launch of Emrosi™, offset by a decrease in Accutane, as a result of lower sales volume driven by recent market competition. Our Legacy products decreased by $0.4 million mainly due to continued generic competition for Targadox.

Gross-to-Net Sales Accruals

We record gross-to-net sales accruals for chargebacks, distributor service fees, prompt pay discounts, sales returns, coupons, managed care rebates, government rebates, and other allowances customary to the pharmaceutical industry.

Gross-to-net sales accruals and the balance in the related allowance accounts for the six-month periods ended June 30, 2025 and 2024, were as follows:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of December 31, 2024 ​ $3,124 ​ $1,750 ​ $3,717 ​ $733 ​ $9,324
Current provision related to sales in the current period ​ (27) ​ 56,150 ​ 11,670 ​ 2,811 ​ 70,604
Checks/credits issued to third parties ​ (598) ​ (51,120) ​ (11,593) ​ (2,725) ​ (66,036)
Balance as of June 30, 2025 ​ $2,499 ​ $6,780 ​ $3,794 ​ $819 ​ $13,892

($'s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Returns ​ ​ ​ ​ ​ ​ ​ ​ Coupons ​ ​ ​ ​ Managed Care Rebates ​ ​ ​ ​ ​ ​ ​ ​ Other ​ ​ ​ ​ ​ ​ ​ ​ Total
Balance as of December 31, 2023 ​ $4,077 ​ $3,444 ​ $5,210 ​ $1,386 ​ $14,117
Current provision related to sales in the current period ​ 1,240 ​ 42,315 ​ 11,213 ​ 3,703 ​ 58,471
Checks/credits issued to third parties ​ (2,103) ​ (43,995) ​ (12,620) ​ (4,060) ​ (62,778)
Balance as of June 30, 2024 ​ $3,214 ​ $1,764 ​ $3,803 ​ $1,029 ​ $9,810

Gross-to-net sales accruals are primarily a function of product sales volume, mix of products sold, and contractual discounts or rebates. Our reserves for gross-to-net sales allowances were $13.9 million at June 30, 2025, compared to $9.3 million at December 31, 2024, an increase of $4.6 million. The increase is due to the coupon rebate allowance related to the launch and commercialization of Emrosi. This is offset, in part, by a decrease in the returns reserve primarily due to lower units on hand in the wholesaler channel.

Cost of Goods Sold - (excluding amortization of acquired intangible assets)

Cost of goods sold - (excluding amortization of acquired intangible assets) decreased by $2.0 million, or 17%, to $9.7 million for the six-month period ended June 30, 2025, from $11.7 million for the six-month period ended June 30, 2024, due to lower overall product cost of goods related to product sales mix, driven mainly by the decrease in Accutane revenue, as well as lower inventory obsolescence costs in the six-month period ended June 30, 2025 of $0.8 million.

Amortization of acquired intangible assets

Amortization of acquired intangible assets increased by $0.5 million, or 31%, to $2.1 million for the six-month period ended June 30, 2025, from $1.6 million for the six-month period ended June 30, 2024, driven by the addition of the Emrosi acquired intangible asset upon our payment to DRL of the milestone payment triggered by the FDA’s approval of Emrosi in November 2024.

Research and Development

Research and development costs were nil for the six months ended June 30, 2025, compared to $8.8 million for the six months ended June 30, 2024. The six months ended June 30, 2024 includes Emrosi pre-approval project expenses, milestones and fees.

Selling, General and Administrative

Selling, general and administrative expenses increased by $3.7 million, or 20%, to $22.4 million for the six-month period ended June 30, 2025, from $18.7 million for the six-month period ended June 30, 2024. The increase is primarily due to the incremental operational activities related to the launch and commercialization of Emrosi.

Interest Expense, net

Interest expense, net increased by $0.8 million, to $1.5 million for the six-month period ended June 30, 2025, from $0.7 million for the six-month period ended June 30, 2024. The increase is primarily attributable to a higher principal balance outstanding under the Credit Agreement with SWK (each as defined below) during the six-months ended June 30, 2025 of $25.0 million as compared to an average balance of approximately $15.0 million during the six-months ended June 30, 2024.

Liquidity and Capital Resources

At June 30, 2025, we had $20.3 million in cash and cash equivalents as compared to $20.3 million of cash and cash equivalents at December 31, 2024, and working capital of $10.8 million at June 30, 2025, compared to $13.0 million at December 31, 2024.

We rely primarily on cash on hand generated from the sales of our pharmaceutical products to our customers to fund our core operations. In addition, we have relied on the proceeds from our term loan Credit Facility (as defined below) with SWK (as defined below) and our at-the-market sales program with B. Riley to meet additional capital and liquidity needs, specifically to fund the research and development and commercialization of Emrosi.

We regularly evaluate market conditions, our liquidity profile, and financing alternatives, including out-licensing arrangements for our products, to enhance our capital structure. We may seek to raise capital through debt or equity financings, which may include sales of securities under either our 2022 Shelf (as defined below) or a new registration statement, to expand our product portfolio and/or for other strategic initiatives. Additionally, as a result of recurring losses, substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months from the date of issuance of these financial statements.

Sources of Liquidity

SWK Credit Facility

On December 27, 2023, we entered into a Credit Agreement (the “Credit Agreement”) with SWK Funding LLC (“SWK”). The Credit Agreement originally provided for a term loan facility (the “Credit Facility”) in the original principal amount of up to $20.0 million. On the closing date, we drew $15.0 million. On June 26, 2024, we drew the remaining $5.0 million under the Credit Facility. Loans under the Credit Facility (the “Term Loans”) mature on December 27, 2027, and bear interest at a rate per annum equal to the three-month term Secured Overnight Financing Rate (“SOFR”) (subject to a SOFR floor of 5%) plus 7.75%. The interest rate resets quarterly. Interest payments began in February 2024 and are paid quarterly. Beginning in February 2026, we are required to repay a portion of the outstanding principal of the Term Loans quarterly in an amount equal to 7.5% of the principal amount of funded Term Loans.

On July 9, 2024, we entered into an amendment (the “Amendment”) to the Credit Agreement. The Amendment increased the original principal amount of the Credit Facility from $20.0 million to $25.0 million. The $5.0 million of additional principal added in the Amendment was contractually required to be drawn upon FDA approval of Emrosi, subject to us receiving approval on or before June 30, 2025. The FDA approved Emrosi on November 1, 2024, and we subsequently drew the remaining $5.0 million. The Credit Facility also includes both revenue and liquidity covenants, restrictions as to payment of dividends, and is secured by substantially all of our assets. As of June 30, 2025, we were in compliance with the financial covenants under the Credit Facility.

At-the-Market Offering

On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333-269079) (the “2022 Shelf”), which was declared effective by the Securities and Exchange Commission on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by us of up to an aggregate of $150.0 million of our common stock, preferred stock, debt securities, warrants, and units. In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) relating to shares of the Company’s common stock with B. Riley Securities, Inc. We may offer and sell up to 4,900,000 shares of our common stock, from time to time, under the Sales Agreement. During the six-months ended June 30, 2025, we issued and sold 834,722 shares of common stock under the 2022 Shelf, generating net proceeds of $4.1 million. At June 30, 2025, 1,752,265 shares remain available for issuance under the Sales Agreement.

Cash Flows for the Six-Month Periods Ended June 30, 2025 and 2024

($’s in thousands)

​ ​ ​ ​ ​ ​ Six-Month Periods Ended June 30, 2025 ​ ​ ​ 2024 ​ ​ ​ ​ Increase (Decrease)
Net cash used in operating activities ​ $(3,774) ​ $(10,195) ​ $6,421
Net cash provided by (used in) investing activities ​ — ​ — ​ —
Net cash provided by financing activities ​ 3,762 ​ 6,668 ​ (2,906)
Net change in cash and cash equivalents ​ $(12) ​ $(3,527) ​ $3,515

Operating Activities

Net cash flows used in operating activities for the six-month period ended June 30, 2025 decreased by $6.4 million, to $3.8 million, from net cash flows used in operating activities of $10.2 million for the six-month period ended June 30, 2024. The decrease was driven primarily by the decrease in our net loss period-to-period, offset by changes in net working capital.

Financing Activities

Net cash flows provided by financing activities for the six-month period ended June 30, 2025 decreased by $2.9 million, to $3.8 million, from $6.7 million of cash flows provided by financing activities for the six-month period ended June 30, 2024. The Company received proceeds from the issuance of common stock under the ATM program of $4.0 million, offset by $0.6 million in payments on installment notes to Sun Pharmaceuticals Industries, Inc. during the six months ended June 30, 2025. The Company received $5.0 million from the SWK Credit Facility and $1.5 million from the issuance of common stock under the ATM program during the six months ended June 30, 2024.

Material Cash Requirements

In the normal course of business, we enter into contractual obligations that contain cash requirements of which the most significant currently include the following:

  • We are required to make regular payments under the SWK Credit Facility. Based on the amount currently outstanding under the SWK facility and current interest rates, and assuming we do not make further draws under the SWK facility, we expect to make the following payments:

($’s in thousands)

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Payments by Period ​ ​ Total ​ ​ ​ ​ Remainder of 2025 ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ ​ ​ ​ 2027
Interest ​ $6,135 ​ $1,629 ​ $2,745 ​ $1,761
Principal ​ 25,000 ​ — ​ 7,500 ​ 17,500
Exit fee ​ 1,250 ​ — ​ — ​ 1,250
Total ​ $32,385 ​ $1,629 ​ $10,245 ​ $20,511
  • We are contractually obligated to pay certain milestone and sales-based royalty payments to the counterparties of our license and product acquisition agreements. Due to the contingent nature of these obligations, the amounts of these payments cannot be reasonably predicted.

Market risk

As filed, 163 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Controls and procedures

As filed, 1,317 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness, as of June 30, 2025, of the design and operation of our disclosure controls and procedures, as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e). Based on this evaluation, our principal executive officer and principal financial officer have concluded that, as of such date, our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

No change in internal control over financial reporting occurred during the most recent quarter with respect to our operations; which materially affected, or is reasonable likely to materially affect, our internal controls over financial reporting.

Risk factors

As filed, 7,543 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We have disclosed below and under the heading “Risk Factors” in the 2024 Form 10-K a number of risks which may materially affect our business, financial condition or results of operations. You should carefully consider these Risk Factors and other information set forth elsewhere in this Quarterly Report on Form 10-Q. You should be aware that these risk factors and other information may not describe every risk facing our Company. Additional risks and uncertainties not currently known to us may also materially adversely affect our business, financial condition and/or results of operations.

The Company’s business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.

Recently there have been significant changes to United States trade policies, sanctions and tariffs, including, but not limited to, trade policies and the imposition of tariffs affecting products imported from outside of the U.S., including pharmaceutical products. This could have negative impacts on our business operations. These changes to trade policies, sanctions and tariffs have led to increased trade and political tensions between the U.S. and other countries in the international community. In response to the U.S. tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Currently, we import a large portion of our finished products from countries outside of the U.S., including, most significantly, from India. These tariffs or any new or additional tariffs on goods imported to the U.S. from India, or other countries, could increase the cost of sourcing of our products and therefore reduce our margins, reduce our net sales and/or cause us to increase prices. Further, the continued threats of tariffs, trade restrictions and trade barriers could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales, overall business and results of operations. The impact of any adopted, new or proposed tariffs, trade restrictions or domestic sourcing requirements on our business is subject to a number of factors that we cannot predict, including, but not limited to, the scope, nature, amount, effective date and duration of any such measures. Such tariffs, trade restrictions or domestic sourcing requirements could have a material adverse effect on our business, prospects, financial condition or results of operations.

Our products and future product candidates may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, which could harm our business.

The ability to successfully commercialize any product candidate that receives marketing authorization depends in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the healthcare industry in the United States and elsewhere is cost containment.

The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the “Affordable Care Act”), was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. We expect that changes to the Affordable Care Act, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate drug prices and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, may result in more rigorous coverage criteria and in additional downward pressure on the price that can be charged for drug products. In addition, on May 12, 2025, President Trump issued an executive order implementing the concept of most-favored nation pricing. Under this order, the Department of Health and Human Services, in coordination with other federal agencies, is directed to take actions to ensure that the price of prescription drugs paid by federal health insurers, including Medicare and Medicaid, is in line with the prices paid in comparably developed nations. Any reduction in reimbursement from Medicare, Medicaid, or other government programs may result in a similar reduction in payments from private payers.

The Inflation Reduction Act of 2022 (the “IRA”) contains substantial drug pricing reforms, including the establishment of a drug price negotiation program within the U.S. Department of Health and Human Services that would require manufacturers to charge a negotiated “maximum fair price” for certain selected drugs or pay an excise tax for noncompliance, the establishment of rebate payment requirements on manufacturers of certain drugs payable under Medicare Parts B and D to penalize price increases that outpace inflation, and requires manufacturers to provide discounts on Part D drugs. Orphan drugs that treat only one rare disease are exempt from the IRA’s drug negotiation program. Substantial penalties can be assessed for noncompliance with the drug pricing provisions in the IRA.

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Additional federal, state and foreign healthcare reform measures will be adopted in the future.

The implementation of any of the cost containment measures or other healthcare reforms discussed above may prevent us from being able to generate revenue, attain profitability or commercialize our products.

Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. It is uncertain whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such may be. In addition, increased Congressional scrutiny of the FDA’s approval process, as well as staffing cuts effected at the FDA in early 2025, may significantly delay or prevent marketing approval, and the industry could become subject to more stringent product labeling and post-marketing testing and other requirements, any of which could have a material adverse impact on the development and commercialization of drug products.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$15.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2025-01-01 to 2025-06-30$28.1mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development6 months2025-01-01 to 2025-06-30$39.0kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2025-04-01 to 2025-06-30$11.9mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2025-01-01 to 2025-06-30$22.5mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2025-04-01 to 2025-06-30−$2.9mus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30−$6.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2025-04-01 to 2025-06-30$937.0kus-gaap:InterestExpenseNonoperating
Interest expense6 months2025-01-01 to 2025-06-30$1.8mus-gaap:InterestExpenseNonoperating
Income tax3 months2025-04-01 to 2025-06-30$60.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-01-01 to 2025-06-30$60.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-04-01 to 2025-06-30−$3.8mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30−$7.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-04-01 to 2025-06-30−$0.16us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-01-01 to 2025-06-30−$0.34us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-04-01 to 2025-06-30−$0.16us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-01-01 to 2025-06-30−$0.34us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-04-01 to 2025-06-3023,290,806 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-01-01 to 2025-06-3022,952,801 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-01-01 to 2025-06-30−$3.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2025-06-30$20.3mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$51.3mus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$81.2mus-gaap:Assets
Current liabilitiesAt period end2025-06-30$40.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-06-30$61.9mus-gaap:Liabilities
Long-term debtAt period end2025-06-30$21.4mus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2025-06-30$3.8mus-gaap:LongTermDebtCurrent
Shareholders' equityAt period end2025-06-30$19.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-25-001703. Last ingested by Listed: Nov 13, 2026, 16:22 ET. Listed shows no prices and gives no investment advice.